We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Collagen Biomarkers Clarify Prognosis of Diabetic Renal Complications

By LabMedica International staff writers
Posted on 24 Jul 2019
Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin. More...
Insulin is a hormone needed to allow sugar (glucose) to enter cells to produce energy.

One cause of kidney failure is diabetes mellitus, a condition characterized by high blood glucose levels. Over time, the high levels of sugar in the blood damage the millions of filtering units within each kidney and this eventually leads to kidney failure. Around 20% to 30% of people with diabetes develop kidney disease (diabetic nephropathy), although not all of these will progress to kidney failure.

A team of scientists working with the Steno Diabetes Center Copenhagen (Gentofte, Denmark) measured by enzyme-linked immunosorbent assay (ELISA) serum and urinary levels of two biomarkers, serum PRO-C6, a biomarker of collagen type VI formation, and urinary C3M, a biomarker of collagen type III degradation. C3M was measured in three urine samples taken between 2009 and 2011 from 663 adults with type 1 diabetes (mean age, 54.6 years; 44% women). The participants were then followed until the end of 2016. During follow-up, the investigators identified instances of cardiovascular (CV) and renal death, nonfatal acute myocardial infarction, nonfatal stroke, coronary interventions, end-stage renal disease, chronic dialysis and kidney transplant as well as measures of estimated glomerular filtration rate (eGFR) from medical records.

The team reported that high levels of serum PRO-C6 were independently associated with a higher risk of all-cause mortality (HR 2.26). Based on median cutoffs, serum PRO-C6 measures of 7.5 ng/mL or more were associated with reduced eGFR, increased urinary albumin excretion rate and greater diabetes duration. The team noted that noted this increased mortality risk was present but only for participants with a urinary albumin excretion rate of less than 30 mg per 24 hours. In addition, an association between serum PRO-C6 and a worsening of 30% or more in eGFR was observed only in participants who had a baseline eGFR of more than 30 mL/min/1.73 m2. The scientists noted that end-stage renal disease (ESRD) was 8.45 times more likely to develop in participants with serum PRO-C6 measures of at least 7.5 ng/mL (HR = 8.45).

Sascha Pilemann-Lyberg, MD, PhD, the first author of the study, and her colleagues said, “Collagens are an essential part of the fibrotic structure, acting as a scaffold for a range of [extracellular matrix] molecule interactions and cell adhesion. “Because increased collagen formation and reduced degradation are closely linked with the development of fibrosis, assessment of collagen formation and degradation may identify patients with active fibrosis at higher risk of CV [events] and heart failure, mortality, and rapid deterioration of kidney function.” The study was published in the July 2019 edition of the journal Diabetes Care.

Related Links:
Steno Diabetes Center Copenhagen


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.